Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation-Reference-Cited by-同舟云学术

Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation

Published:2016-11 Issue:35 Volume:20 Page:611-614
ISSN:1366-5278
Container-title:Health Technology Assessment
language:en
Short-container-title:Health Technol Assess

Author:

Stevenson Matt¹,Archer Rachel¹,Tosh Jon¹,Simpson Emma¹,Everson-Hock Emma¹,Stevens John¹,Hernandez-Alava Monica¹,Paisley Suzy¹,Dickinson Kath¹,Scott David²,Young Adam³,Wailoo Allan¹

Affiliation:

1. School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

2. Department of Rheumatology, King’s College Hospital NHS Foundation Trust, London, UK

3. Department of Rheumatology, West Hertfordshire Hospitals NHS Trust, Hertfordshire, UK

Abstract

Abstract Correction to Table 209.

Funder

Health Technology Assessment programme

Publisher

National Institute for Health Research

Subject

Health Policy

Reference1 articles.

1. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation;Stevenson;Health Technol Assess,2016

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of refractory disease and persistent symptoms in inflammatory arthritis: qualitative framework analysis of interviews with patients and healthcare professionals;Rheumatology Advances in Practice;2024

2. A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate;Journal of Health Economics and Outcomes Research;2020-04-10

3. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal;PharmacoEconomics;2018-06-08

4. PP001 Ultrasound To Guide Treatment Decisions In Rheumatoid Arthritis;International Journal of Technology Assessment in Health Care;2017